Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Queensland Health
Cantor Fitzgerald
Johnson and Johnson
UBS
Colorcon
Federal Trade Commission
Baxter
Accenture
Daiichi Sankyo

Generated: January 19, 2018

DrugPatentWatch Database Preview

Vismodegib - Generic Drug Details

« Back to Dashboard

What are the generic sources for vismodegib and what is the scope of vismodegib patent protection?

Vismodegib
is the generic ingredient in one branded drug marketed by Genentech and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vismodegib has forty-three patent family members in twenty-two countries.

One supplier is listed for this compound.
Summary for vismodegib
Pharmacology for vismodegib

US Patents and Regulatory Information for vismodegib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for vismodegib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,321,761 Pyridyl inhibitors of hedgehog signalling ➤ Subscribe
9,790,183 Pyridyl inhibitors of hedgehog signalling ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for vismodegib

Supplementary Protection Certificates for vismodegib

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1789390/01 Switzerland ➤ Subscribe PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013
2013024 Lithuania ➤ Subscribe PRODUCT NAME: VISMODEGIBUM; NAT. REGISTRATION NO/DATE: SWISS 62497 01 20130530; FIRST REGISTRATION: EU/1/13/848 20130712
2013000074 Germany ➤ Subscribe PRODUCT NAME: ERIVEDGE - VISMODEGIB; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: SCHWEIZ IKS-NR. 62497 20130530
0130027 00083 Estonia ➤ Subscribe PRODUCT NAME: VISMODEGIIB;REG NO/DATE: K(2013)4550 (LOPLIK) 12.07.2013
4 Finland ➤ Subscribe
2013 00050 Denmark ➤ Subscribe PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
2013 00050 Denmark ➤ Subscribe PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
14/002 Ireland ➤ Subscribe PRODUCT NAME: ERIVEDGE-VISMODEGIB OR A SALT OR SOLVATE THEREOF; NAT REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION NO/DATE: 62497 01 20130530
C0002 France ➤ Subscribe PRODUCT NAME: VISMODEGIB AINSI QUE SES SELS ET SOLVATES; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: IKS 62497 20130530
0 12-2013 Slovakia ➤ Subscribe PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848/001 20130712
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cipla
Fish and Richardson
Argus Health
US Army
Mallinckrodt
Johnson and Johnson
Moodys
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot